PharmaShots | Incisive News in 3 Shots

Subscribe Now

mantle cell lymphoma

BeiGene's Brukinsa (Zanubrutinib) Receives Health Canada's Approval for Mantle Cell Lymphoma

BeiGene's Brukinsa (Zanubrutinib) Receives Health Canada's Approval for Mantle Cell Lymphoma

July 27, 2021

BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting

November 5, 2020

$Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma$

Kite's KTE-X19 Receives the US FDA's Priority Review for Relapsed or Refractory Mantle Cell Lymphoma

February 11, 2020

$Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma$

Kite Reports the Validation of EMA's MAA for KTE-X19 to Treat Relapsed or Refractory Mantle Cell Lymphoma

January 29, 2020

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received At least One Prior Therapy

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for Patients with Mantle Cell Lymphoma Who Received A...

November 15, 2019

Beigene's Zanubrutinib (BGB-3111) Receives the US FDA's Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)

Beigene's Zanubrutinib (BGB-3111) Receives the US FDA's Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)

January 16, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us